23541-50-6 Usage
Description
Daunorubicin hydrochloride, also known as Daunorubicin HCl, is an anthracycline antibiotic related to the rhodomycins. It is an anti-neoplastic agent used in the treatment of acute myeloid leukemias. Daunorubicin hydrochloride is an orange-red powder that forms thin red needles, which decompose at 188-190°C. It is a potent DNA intercalator that may suppress acute leukemia proliferation and induces apoptosis in a variety of cell lines. The drug is available in 20and 100-mg vials for reconstitution and is administered intravenously. Daunorubicin hydrochloride lacks the hydroxyl groups found at C-14 of doxorubicin, leading to an increase in the alcohol metabolite daunorubicinol (active) arising from the reduction of the side chain ketone. However, this does not appear to result in a significant increase in cardiotoxicity compared to doxorubicin. A liposomal form of daunorubicin, known as DaunoXome, is also available, offering the same advantages as the liposomal form of doxorubicin.
Uses
1. Used in Anticancer Applications:
Daunorubicin hydrochloride is used as an antineoplastic agent for the treatment of acute nonlymphocytic and lymphocytic leukemia. It is particularly effective against solid malignancies such as leukemia and may also be used for other unlabeled uses, including chronic myeloid leukemia (CML) and Kaposi sarcoma.
2. Used in DNA Intercalation:
Daunorubicin hydrochloride is used as a DNA intercalator, which may suppress acute leukemia proliferation by inducing DNA damage and apoptosis in a variety of cell lines.
3. Used in Apoptosis Induction:
Daunorubicin hydrochloride is used to induce apoptosis in various cell lines, contributing to its antineoplastic effects.
4. Used in Autophagy Inhibition:
Inhibition of autophagy with chloroquine enhances daunorubicin-induced apoptosis in K562 cells, further contributing to its antineoplastic properties.
5. Used in Liposomal Drug Delivery:
A liposomal form of daunorubicin, known as DaunoXome, is used to improve the drug's delivery, bioavailability, and therapeutic outcomes in cancer treatment.
Originator
Cerubidine,Rhone-Poulenc Rorer,France
Manufacturing Process
A 170 liter fermentation vessel is charged with:Corn steep2.400 kgSucrose3.600 kgCalcium carbonate0.900 kgAmmonium sulphate 0.240 kgWaterto 100 litersThis culture medium has a pH of 6.15. It is sterilised by passage of steam at
122°C for 40 minutes. After cooling, the volume of the broth is 120 liters and
the pH is 7.20. The medium is then seeded with 200 cc of a culture of the
strain Streptomyces 31723. The culture is carried out for 27 hours at 26°-
27°C with agitation and aeration with sterile air. It is then suitable for seeding
the production culture. The production culture is carried out in an 800 liter
formentation vessel charged with the following:Soya flour 20 kgDistillers' solubles 2.500 kgSoya oil 2.500 litersSoya oil 2.500 litersSodium chloride 5 kgWater to 465 litersStarch 10 kgThe pH of the medium thus obtained is adjusted to 7.20 with concentrated
sodium hydroxide solution (400 cc). The medium is then sterilised by the
passage of steam at 122°C for 40 minutes. After cooling, the volume of the
broth is 500 liters and the pH is 6.75. It is then seeded with 50 liters of the
culture from the 170 liter fermentation vessel. Culture is carried out at 28°C
for 67 hours with agitation and aeration with sterile air. The pH of the medium
is then 7.40 and the volume of the fermentation culture is 520 liters. The
quantitiy of antibiotic present in the medium is 29 μ/cc.The above fermentation culture (520 liters; activity 29 μ/cc) is placed in a
vessel equipped with an agitator and the pH is adjusted to 1.8 with a
concentrated solution of oxalic acid. Agitation is carried out for one hour and a
filtration adjuvant (20 kg) then added. The mixture is filtered on a filter-press
and the filter-cake washed with water (100 liters) acidified to pH 2 with oxalic
acid. The filtrate (612 liters) is treated with concentrated sodium hydroxide
solution until the pH is 4.5. The filtrate is then passed through a column
containing Amberlite IRC 50 in hydrogen form (20 liters; diameter of column
15.2 cm, height of column 200 cm, height of resin at rest in column 110 cm).
The filtrate passes through the bed of Amberlite from base to top at a rate of
40 liters/hour. The column is then washed with water (100 liters) at a rate of
50 liters/hour circulating from base to top and then with methanol (containing
10% water; 75 liters) circulating from top to base at a rate of 50 liters/hour.
The washings are discarded and the column is then eluted with a solution
having the following composition (per liter):The eluate (100 liters), which contains the major part of the antibiotic, is
concentrated under reduced pressure at 35°C to 10 liters. The concentrate is
extracted at pH 7.5 with chloroform (2 times 5 liters). The chloroformic
extract is adjusted to pH 4 with a solution of acetic acid in chloroform (10:100
by volume) and then concentrated at 30°C under reduced pressure to 100 cc.
The antibiotic is precipitated by the addition of hexane (1 liter), separated,
washed and dried to give an amorphous red powder (9 g) of activity 1,400
μ/mg.The crude antibiotic (17.1 g) obtained as above described (activity 1530
μ/mg) is dissolved with stirring in a mixture of methylene chloride (1.5 liters),
carbon tetrachloride (0.3 liters) and water (1.8 liters). The pH is then adjusted9865 RP (500 mg), obtained as above described, is dissolved in normal
sulphuric acid (100 cc) and the solution obtained is heated for 20 minutes on
a water-bath. After cooling and extracting with ethyl acetate (3 times 200 cc),
the organic extract is dried over anhydrous sodium sulphate, filtered and
concentrated to a small volume, giving, after filtering, washing and drying,
crystals (218.5 mg). These crystals (150 mg) are dissolved in chloroform (3
cc) and benzene (1.5 cc) and the solution obtained is chromatographed on 20
sheets of Arches No. 310 paper impregnated with a solution of acetone
containing 20% formamide, and developed for 90 minutes by means of a 2:1
mixture of chloroform and benzene saturatd with formamide. The principal
zone of Rf = 0.86 is cut out of each of the 20 sheets and the 20 zones thus
cut out are comminuted in a mixer in the presence of methanol. The mixture
obtained is filtered, concentrated, and water (10 volumes) added. The
precipitate obtained is filtered off, washed and dried under reduced pressure
to give crystals (120 mg). These crystals (170 mg) are dissolved in dioxan
containing 20% water (15 cc) and water acidified to pH 4 with 0.1 N
hydrochloric acid is added dropwise. The crystals formed are filtered off,
washed and dried, thus giving the aglycone of 9865 RP (130 mg) in the form
of orange-red needles, having a first melting point at 160°C and a second at
225°C-230°C.Daudorubicin can be prepared by gene ingineering methods also.
to 3 by the addition of normal hydrochloric acid (8 cc). After decanting, the
aqueous phase is treated with methylene chloride (7 liters) and 0.1 N sodium
hydroxide solution (200 cc) to give a pH of 7.5. After decanting, the aqueous
phase is again extracted at pH 7.5 with methylene chloride (3.5 liters). The
methylene chloride extracts are combined and concentrated to 100 cc. After
the addition of hexane (1 liter) to the concentrate, a product precipitates which is filtered off, washed and dried at 30°C under reduced pressure to give
the antibiotic 9865 RP (9.15 g) in the form of an amorphous orange-red
powder of activity 2180 μ/mg.
Therapeutic Function
Antineoplastic
Air & Water Reactions
Water soluble.
Reactivity Profile
Daunorubicin hydrochloride may emit toxic oxides of nitrogen when heated.
Biological Activity
Anticancer agent that is clinically used to treat nonlymphocytic leukaemia. Inhibits RNA and DNA synthesis and causes DNA fragmentation in vivo .
Biochem/physiol Actions
Potent anticancer agent. Inhibits DNA and RNA synthesis as sequence specific ds-DNA intercalating agent.
Pharmacokinetics
Like Doxil (the liposomal formulation of doxorubicin), DaunoXome is indicated for use in AIDS-related Kaposi's sarcoma and is administered IV at a dose of 40 mg/m2 every 2 weeks. The pharmacokinetic profiles of Doxil and DaunoXome are similar.
Clinical Use
Daunorubicin is administered IV at a dose of 45 mg/m2 for the treatment of lymphocytic and nonlymphocytic leukemia.
Metabolism
The 18.5-hour terminal half-life of daunorubicin is approximately half that of doxorubicin, and the terminal half-life of the active daunorubicinol metabolite is 26.7 hours. Excretion is approximately 40% biliary and 25% urinary.
References
1) Laurent and Jaffrezou (2001),?Signaling pathways activated by daunorubicin; Blood?98?913
2) Yang et al. (2014), Doxorubicin, DNA torsion, and chromatin dynamics; Biochim.Biophys.Acta, 1845 84
3) Masquelier?et al.?(2004),?Relationship between daunorubicin concentration and apoptosis induction in leukemic cells; Biochem.Pharmacol.?67?1047
4) Han?et al.?(2011),?Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells; PLoS One?6?e28491
Check Digit Verification of cas no
The CAS Registry Mumber 23541-50-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,5,4 and 1 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 23541-50:
(7*2)+(6*3)+(5*5)+(4*4)+(3*1)+(2*5)+(1*0)=86
86 % 10 = 6
So 23541-50-6 is a valid CAS Registry Number.
InChI:InChI=1/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17-,22+,27-;/m1./s1
23541-50-6Relevant articles and documents
Anti-cancer drug aldehyde conjugate drugs with enhanced cytotoxicity compounds, compositions and methods
-
Page/Page column 17; 18; 56, (2010/02/05)
Monomeric and dimeric anti-cancer drug aldehyde conjugate compounds and pharmaceutically acceptable salts thereof. Specifically, monomeric and dimeric aldehyde conjugates of 1-2, dihetero-substituted anti-cancer drugs, including monomeric and dimeric aldehyde conjugates of anthracyclines, are provided. Also provided are pro-drugs which, after administration, release monomeric aldehyde conjugates. Further provided are pharmaceutical and therapeutic compositions containing anti-cancer drug aldehyde conjugates and methods of treating cancer using the aldehyde conjugates.
SYNTHESIS AND PROPERTIES OF HYDRAZONES OF THE ANTITUMOR ANTIBIOTIC RUBOMYCIN
Rozin, Yu. A.,Buryndina, E. I.,Batulina, R. Kh.,Bobrova, T. M.,Krupnova, L. V.,Barybin, A. S.
, p. 398 - 402 (2007/10/02)
-
Process for preparing daunomycin and analogues thereof
-
, (2008/06/13)
Racemic anthracyclinones of the general formula II STR1 when condensed with 2,3,6-trideoxy-3-trifluoroacetamido-4-0-trifluoroacetyl-α-L-lyxo-pyranosyl chloride in the presence of silver trifluoromethane sulphonate yield an easily separable mixture of equimolar amounts of exclusively the α-glycoside of the 7S : 9S diastereomer and the β-glycoside of the 7R : 9R diastereomer. In this way the biologically important α-glycosides of the 7S : 9S diastereomer of the general formula I (below) are easily prepared from a racemic anthracyclinone.
